Continue to site >
Trending ETFs

Name

As of 05/12/2023

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$11.61

$52.3 M

0.00%

0.50%

Vitals

YTD Return

6.7%

1 yr return

10.3%

3 Yr Avg Return

0.4%

5 Yr Avg Return

N/A

Net Assets

$52.3 M

Holdings in Top 10

39.7%

52 WEEK LOW AND HIGH

$11.7
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 0.50%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 44.00%

Redemption Fee N/A


Min Investment

Standard (Taxable)

$0

IRA

N/A


Fund Classification

Fund Type

Open End Mutual Fund


Name

As of 05/12/2023

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$11.61

$52.3 M

0.00%

0.50%

FRXMX - Profile

Distributions

  • YTD Total Return 6.7%
  • 3 Yr Annualized Total Return 0.4%
  • 5 Yr Annualized Total Return N/A
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio -0.11%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Fidelity® Disruptive Medicine Fund
  • Fund Family Name
    Fidelity Investments
  • Inception Date
    Apr 16, 2020
  • Shares Outstanding
    N/A
  • Share Class
    Other
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Michael Kim

Fund Description

Normally investing at least 80% of assets in securities of disruptive medicine companies. Fidelity’s disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. This may include creating, providing, or contributing to new or expanded business models, value networks, pricing, and delivery of products and services. Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser’s opinion, are engaged in robotic surgery, cell and gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, advanced diagnostics and consumer wellness. In pursuing this investment theme, the fund may invest in companies in any economic sector. Although the fund may invest across economic sectors, the fund concentrates its investments in the health care industries. Normally investing primarily in equity securities. Using fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions, to select investments with quantitative portfolio construction. Investing in either "growth" stocks or "value" stocks or both. Investing in securities of domestic and foreign issuers.
Read More

FRXMX - Performance

Return Ranking - Trailing

Period FRXMX Return Category Return Low Category Return High Rank in Category (%)
YTD 6.7% -11.3% 22.2% 11.24%
1 Yr 10.3% -25.3% 34.3% 15.98%
3 Yr 0.4%* -21.1% 15.7% 30.63%
5 Yr N/A* -14.9% 12.1% N/A
10 Yr N/A* -6.6% 15.9% N/A

* Annualized

Return Ranking - Calendar

Period FRXMX Return Category Return Low Category Return High Rank in Category (%)
2023 -21.4% -53.9% 5.0% 85.44%
2022 5.1% -22.3% 12.3% 20.89%
2021 N/A -4.7% 41.4% N/A
2020 N/A -10.2% 13.1% N/A
2019 N/A -5.7% 16.7% N/A

Total Return Ranking - Trailing

Period FRXMX Return Category Return Low Category Return High Rank in Category (%)
YTD 6.7% -50.0% 17.9% 8.28%
1 Yr 10.3% -60.2% 34.3% 16.47%
3 Yr 0.4%* -21.1% 17.8% 35.90%
5 Yr N/A* -14.9% 16.9% N/A
10 Yr N/A* -6.6% 18.5% N/A

* Annualized

Total Return Ranking - Calendar

Period FRXMX Return Category Return Low Category Return High Rank in Category (%)
2023 -21.4% -53.9% 5.0% 85.44%
2022 5.1% -22.3% 12.3% 20.89%
2021 N/A -4.7% 41.4% N/A
2020 N/A -10.2% 13.1% N/A
2019 N/A -5.7% 16.7% N/A

NAV & Total Return History


FRXMX - Holdings

Concentration Analysis

FRXMX Category Low Category High FRXMX % Rank
Net Assets 52.3 M 1.02 M 46.2 B 78.70%
Number of Holdings 71 25 473 57.58%
Net Assets in Top 10 22.2 M 1.78 M 21.6 B 78.79%
Weighting of Top 10 39.67% 12.3% 80.8% 80.00%

Top 10 Holdings

  1. Regeneron Pharmaceuticals Inc 5.69%
  2. Regeneron Pharmaceuticals Inc 5.69%
  3. Regeneron Pharmaceuticals Inc 5.69%
  4. Regeneron Pharmaceuticals Inc 5.69%
  5. Regeneron Pharmaceuticals Inc 5.69%
  6. Regeneron Pharmaceuticals Inc 5.69%
  7. Regeneron Pharmaceuticals Inc 5.69%
  8. Regeneron Pharmaceuticals Inc 5.69%
  9. Regeneron Pharmaceuticals Inc 5.69%
  10. Regeneron Pharmaceuticals Inc 5.69%

Asset Allocation

Weighting Return Low Return High FRXMX % Rank
Stocks
98.52% 85.37% 106.13% 51.52%
Cash
1.48% -0.04% 9.01% 40.00%
Preferred Stocks
0.00% 0.00% 7.86% 87.88%
Other
0.00% -22.99% 3.38% 81.82%
Convertible Bonds
0.00% 0.00% 0.37% 87.27%
Bonds
0.00% 0.00% 12.39% 87.27%

Stock Sector Breakdown

Weighting Return Low Return High FRXMX % Rank
Healthcare
100.00% 59.26% 100.00% 39.39%
Utilities
0.00% 0.00% 0.00% 86.67%
Technology
0.00% 0.00% 22.69% 89.70%
Real Estate
0.00% 0.00% 5.89% 88.48%
Industrials
0.00% 0.00% 7.02% 88.48%
Financial Services
0.00% 0.00% 1.60% 88.48%
Energy
0.00% 0.00% 0.00% 86.67%
Communication Services
0.00% 0.00% 9.11% 86.67%
Consumer Defense
0.00% 0.00% 25.73% 89.09%
Consumer Cyclical
0.00% 0.00% 1.92% 88.48%
Basic Materials
0.00% 0.00% 7.16% 90.30%

Stock Geographic Breakdown

Weighting Return Low Return High FRXMX % Rank
US
90.06% 53.67% 104.41% 33.33%
Non US
8.46% 0.00% 45.40% 63.03%

FRXMX - Expenses

Operational Fees

FRXMX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.50% 0.08% 33.47% 84.15%
Management Fee 0.50% 0.00% 1.25% 18.93%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

FRXMX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 0.00% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

FRXMX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FRXMX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 44.00% 0.00% 238.00% 45.83%

FRXMX - Distributions

Dividend Yield Analysis

FRXMX Category Low Category High FRXMX % Rank
Dividend Yield 0.00% 0.00% 2.34% 89.41%

Dividend Distribution Analysis

FRXMX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Semi-Annually Annually

Net Income Ratio Analysis

FRXMX Category Low Category High FRXMX % Rank
Net Income Ratio -0.11% -2.54% 1.85% 43.83%

Capital Gain Distribution Analysis

FRXMX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Semi-Annually Annually

Distributions History

View More +

FRXMX - Fund Manager Analysis

Managers

Michael Kim


Start Date

Tenure

Tenure Rank

Apr 16, 2020

2.12

2.1%

Michael Kim is a quantitative analyst and portfolio manager in the Equity division at Fidelity Investments. Fidelity Investments is a leading provider of investment management, retirement planning, portfolio guidance, brokerage, benefits outsourcing, and other financial products and services to institutions, financial intermediaries, and individuals.

Fahim Razzaque


Start Date

Tenure

Tenure Rank

Apr 16, 2020

2.12

2.1%

Fahim Razzaque is co-manager of the fund, which he has managed since November 2019. Since joining Fidelity Investments in 2008, Mr. Razzaque has worked as a managing director of research, research analyst, and portfolio manager.

Christopher Lee


Start Date

Tenure

Tenure Rank

Apr 16, 2020

2.12

2.1%

Lee is portfolio manager at Fidelity. Since joining Fidelity in 2004 as an equity analyst, Lee has been following companies in the semiconductor sector. He previously served as an analyst intern for Minot Capital Management in Boston during the summer of 2003. From 1999 to 2002, he was an associate in the Technology Group for TA Associates, a private equity firm in Boston. Lee began his career at Robertson Stephens, where he served as a financial analyst in the Technology Group from 1997-1999.

Camille Carlstrom


Start Date

Tenure

Tenure Rank

Apr 16, 2020

2.12

2.1%

Camille Carlstrom is a portfolio manager at Fidelity Institutional Asset Management (FIAM), an investment organization within Fidelity Investments’ asset management division that is dedicated to serving the needs of consultants and institutional investors, such as defined benefit and defined contribution plans, endowments and financial advisors. In this role, Ms. Carlstrom is the lead portfolio manager of the FIAM International Growth strategy and is in charge of asset allocation and risk control across the portfolio.

William Shanley


Start Date

Tenure

Tenure Rank

Apr 16, 2020

2.12

2.1%

William Shanley is co-manager of the fund, which he has managed since November 2019. Since joining Fidelity Investments in 2004, Mr. Shanley has worked as a managing director of research, research analyst and portfolio manager.

Charles Hebard


Start Date

Tenure

Tenure Rank

Apr 16, 2020

2.12

2.1%

Charlie Hebard is co-manager of each fund, which he has managed since April 2020. He also manages other funds. Since joining Fidelity Investments in 1999, Mr. Hebard has worked as a managing director of research and portfolio manager. Prior to joining Fidelity, Hebard was an assistant vice president for CiticorpSecurities Inc. in the Global Media and Communications division, from 1996 to 1997.

Niamh Brodie-Machura


Start Date

Tenure

Tenure Rank

Jul 31, 2020

1.83

1.8%

Timothy Codrington


Start Date

Tenure

Tenure Rank

Nov 30, 2020

1.5

1.5%

"Timothy Codrington is a Portfolio Manager at Copper Rock Capital Partners. He joined the firm in February of 2015 and is responsible for fundamental investment research, stock selection and portfolio construction across all of the firm’s investment strategies. Prior to joining Copper Rock, Tim worked at AGF Management Limited Canada where he was an Associate Portfolio Manager on the Global Equity team. In this role, he oversaw Global and Emerging Markets investments for approximately $7 billion in assets under management across three funds: a Global Core Fund, a Global Dividend Fund, and an Emerging Markets Fund. He was also responsible for fundamental research of global securities in the Consumer Staples and Cyclicals sectors. Prior to AGF, Tim was a Senior Vice President and Portfolio Manager on a variety of International and Global Investment strategies at Putnam Investments. He received his B.A. from Harvard University and is also a graduate of the Harvard Business School. He has over 15 years of fundamental research and portfolio management experience. "

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.39 0.25